- Home
- FENC vs NGEN Comparison
FENC vs NGEN Comparison
Compare FENC & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | NGEN |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 9 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 197.5M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENC | NGEN |
|---|---|---|
| Price | $10.11 | $1.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $14.50 | ★ $18.00 |
| AVG Volume (30 Days) | 193.6K | ★ 817.0K |
| Earning Date | 05-12-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $1,015.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $1.59 |
| 52 Week High | $11.31 | $5.93 |
Technical Indicators
Market Signals| Indicator | FENC | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.70 | 33.00 |
| Support Level | $10.04 | N/A |
| Resistance Level | $10.45 | $2.28 |
| Average True Range (ATR) | 0.56 | 0.13 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 20.07 | 5.88 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.